- Previous Close
28.99 - Open
28.75 - Bid 28.41 x 100
- Ask 28.58 x 200
- Day's Range
28.37 - 30.20 - 52 Week Range
26.66 - 52.68 - Volume
619,755 - Avg. Volume
827,654 - Market Cap (intraday)
1.407B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
64.91 - EPS (TTM)
0.44 - Earnings Date Oct 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
46.64
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
www.staar.com1,056
Full Time Employees
December 29
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: STAA
View More
Performance Overview: STAA
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STAA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STAA
View MoreValuation Measures
Market Cap
1.41B
Enterprise Value
1.21B
Trailing P/E
64.91
Forward P/E
555.56
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.14
Price/Book (mrq)
3.29
Enterprise Value/Revenue
3.55
Enterprise Value/EBITDA
38.54
Financial Highlights
Profitability and Income Statement
Profit Margin
6.38%
Return on Assets (ttm)
3.39%
Return on Equity (ttm)
5.40%
Revenue (ttm)
341.22M
Net Income Avi to Common (ttm)
21.78M
Diluted EPS (ttm)
0.44
Balance Sheet and Cash Flow
Total Cash (mrq)
235.96M
Total Debt/Equity (mrq)
9.34%
Levered Free Cash Flow (ttm)
31.72M
Research Analysis: STAA
View MoreCompany Insights: STAA
STAA does not have Company Insights
Research Reports: STAA
View MoreRating decreased to a SELL
STAAR SURGICAL CO has an Investment Rating of SELL; a target price of $24.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $32.00
STAAR SURGICAL CO has an Investment Rating of HOLD; a target price of $32.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $34.00
STAAR SURGICAL CO has an Investment Rating of HOLD; a target price of $34.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRating increased to a HOLD
STAAR SURGICAL CO has an Investment Rating of HOLD; a target price of $33.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target